Submitted by amarin on Wed, 04/11/2018 - 19:44 Home ID Reference 15196 News title Amarin's REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events
